Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evogene (EVGN)
NASDAQ:EVGN
Holding EVGN?
Track your performance easily
EVGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.20 - $10.40
Previous Close$1.45
Volume136.57K
Average Volume (3M)296.50K
Market Cap
$7.78M
Enterprise Value-$5.51M
Total Cash (Recent Filing)$31.06M
Total Debt (Recent Filing)$1.14M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Mar 06, 2025EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.45
Shares Outstanding5,079,000
10 Day Avg. Volume65,649
30 Day Avg. Volume296,495
Standard Deviation0.27
R-Squared0.07
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.61
Price to Sales (P/S)1.31
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-7.09
Enterprise Value/Gross Profit-1.40
Enterprise Value/Ebitda0.42
Forecast
1Y Price Target
$8.13Price Target Upside381.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Evogene News
PremiumCompany Announcements
Evogene’s Lavie Bio Retains Tech Amid Corteva Exit
PremiumCompany Announcements
Evogene Sees Revenue Growth and Expands AI Collaboration
Bulls Say, Bears Say
Bulls Say
Business DevelopmentCasterra is believed to be a potential catalyst for the stock via commercial successes, with material value also seen in AgPlenus and Lavie Bio.
Cost ControlsCost controls have appropriately been implemented, leading to a lower than expected operating expense and an EBITDA beat despite lower revenues.
Investment OpportunitiesCasterra, AgPlenus, and Lavie Bio are seen as potential catalysts for the stock, with opportunities for subsidiary-level investment or monetization.
Bears Say
Dilution ImpactThe diluted share base effectively doubled due to a $5.5M raise, contributing to the decision to lower the price target.
Order DelaysDelays in current order delivery and a follow-on order continue to be a material headwind for investors.
Price Target ReductionThe price target is lowered from $12 to $5 due to delayed commercial ramp and dilution.
---
Ownership Overview
―
Insiders
0.11% Mutual Funds
9.55% Other Institutional Investors
89.18% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EVGN FAQ
What was Evogene’s price range in the past 12 months?
Evogene lowest stock price was $1.20 and its highest was $10.40 in the past 12 months.
What is Evogene’s market cap?
Currently, no data Available
When is Evogene’s upcoming earnings report date?
Evogene’s upcoming earnings report date is Mar 06, 2025 which is in 69 days.
How were Evogene’s earnings last quarter?
Evogene released its earnings results on Nov 21, 2024. The company reported -$1.31 earnings per share for the quarter, missing the consensus estimate of -$1.01 by -$0.3.
Is Evogene overvalued?
According to Wall Street analysts Evogene’s price is currently Undervalued.
Does Evogene pay dividends?
Evogene does not currently pay dividends.
What is Evogene’s EPS estimate?
Evogene’s EPS estimate is -$0.73.
How many shares outstanding does Evogene have?
Evogene has 5,365,438 shares outstanding.
What happened to Evogene’s price movement after its last earnings report?
Evogene reported an EPS of -$1.31 in its last earnings report, missing expectations of -$1.01. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Evogene?
Among the largest hedge funds holding Evogene’s share is ARK Investment Management LLC. It holds Evogene’s shares valued at N/A.
---
Company Description
Evogene
Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure that is based on deep scientific understanding of plant genomics and proprietary computational capabilities. The company was founded by Amir Barzilay and Hagai Karchi in 2002 and is headquartered in Rehovot, Israel.
---
EVGN Stock 12 Month Forecast
Average Price Target
$8.13
▲(381.07% Upside)
Technical Analysis
Best Analysts Covering EVGN
1 Year
1 Year Success Rate
1/16 ratings generated profit
1 Year Average Return
-58.76%
reiterated a buy rating last month
Copying Ben Klieve's trades and holding each position for 1 Year would result in 6.25% of your transactions generating a profit, with an average return of -58.76% per trade.
---